American Made Medicine Act

The American Made Medicine Act, also known as Bill 117 hr 7410, is a piece of legislation introduced in the US Congress with the aim of promoting the manufacturing of pharmaceuticals in the United States. The bill seeks to incentivize pharmaceutical companies to produce their products domestically by providing tax breaks and other financial incentives.

One of the key provisions of the American Made Medicine Act is the establishment of a tax credit for pharmaceutical companies that manufacture their products in the US. This tax credit would help offset the costs associated with domestic production and make it more financially viable for companies to produce their drugs in the United States.

Additionally, the bill includes measures to streamline the regulatory process for pharmaceutical companies looking to manufacture their products domestically. This would help reduce the time and resources needed to get approval for manufacturing facilities in the US, making it easier for companies to transition their production operations to American soil. Overall, the American Made Medicine Act aims to boost the domestic pharmaceutical industry and create more jobs in the United States. By providing incentives for companies to manufacture their products domestically and streamlining the regulatory process, the bill seeks to strengthen the country's pharmaceutical supply chain and reduce reliance on foreign manufacturers.